IDEXX Laboratories, Inc. (IDXX) Presents at 47th Annual Raymond James Institutional Investor Conference Prepared Remarks Transcript

IDEXX Laboratories, Inc. (IDXX) 47th Annual Raymond James Institutional Investor Conference March 2, 2026 9:15 AM ESTCompany ParticipantsJay Mazelsky ...

IDEXX Laboratories, Inc. (IDXX) Presents at BofA Securities Animal Health Summit Transcript

BofA Securities Animal Health Summit February 26, 2026 9:50 AM ESTCompany ParticipantsAndrew Emerson - Executive VP, ...
PharmiWeb

Innovative Injectable Therapies Transform the Future of the Weight Loss Drugs Market

OverviewThe Global Weight Loss Drugs Market is valued at USD 2.88 Billion in 2024 and is projected to reach a value of USD ...
PharmiWeb

PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

In the Phase 3 EV-304 trial, statistically significant improvements in overall survival and pathological complete response were also observed, with over half of patients having no detectable disease ...

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligibl…

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA® (pembrolizumab) plus ...
Le Lézard

PADCEVtm + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

Pfizer Inc. and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced positive results from the Phase 3 EV-304 clinical trial (also known as KEYNOTE-B15) for ...